{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=17&q=hormone+receptor-positive", "query": { "q": "hormone receptor-positive", "condition": "Breast Cancer", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=18&q=hormone+receptor-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=16&q=hormone+receptor-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:29:58.297Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02213042", "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Aromatase Inhibitors (AIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2014-10-24", "completion_date": "2020-06-04", "has_results": true, "last_update_posted_date": "2021-10-13", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 3, "location_summary": "Mobile, Alabama • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213042" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" }, { "nct_id": "NCT04086875", "title": "A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor Positive Tumor", "Progesterone Receptor Positive Tumor", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8" ], "interventions": [ { "name": "Focus Group", "type": "BEHAVIORAL" }, { "name": "Text Message", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 332, "start_date": "2018-11-07", "completion_date": "2024-09-24", "has_results": false, "last_update_posted_date": "2024-06-10", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 7, "location_summary": "Sewell, New Jersey • Abington, Pennsylvania • Doylestown, Pennsylvania + 1 more", "locations": [ { "city": "Sewell", "state": "New Jersey" }, { "city": "Abington", "state": "Pennsylvania" }, { "city": "Doylestown", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04086875" }, { "nct_id": "NCT03493854", "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab IV", "type": "DRUG" }, { "name": "FDC of Pertuzumab and Trastuzumab SC", "type": "DRUG" }, { "name": "Trastuzumab IV", "type": "DRUG" }, { "name": "Trastuzumab SC", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Post-operative Radiotherapy", "type": "RADIATION" }, { "name": "Hormone Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2018-06-14", "completion_date": "2023-06-02", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 4, "location_summary": "Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Rockville", "state": "Maryland" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Lakewood", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493854" }, { "nct_id": "NCT07227831", "title": "A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Advanced Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "TheraBionic P1", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 82, "start_date": "2026-01-16", "completion_date": "2028-05-22", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 8, "location_summary": "Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 5 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Clarkston", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Flint", "state": "Michigan" }, { "city": "Lapeer", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227831" }, { "nct_id": "NCT03628066", "title": "Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Oncotype DX Breast Recurrence Score", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2018-10-22", "completion_date": "2021-01-30", "has_results": false, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 11, "location_summary": "Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03628066" }, { "nct_id": "NCT03280303", "title": "Palbociclib in Real World Practice", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "non-interventional", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1285, "start_date": "2017-01-04", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-09-20", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 301, "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 224 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03280303" }, { "nct_id": "NCT01900418", "title": "Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Joint Pain", "Breast Cancer" ], "interventions": [ { "name": "Walk with Ease", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "21 Years to 99 Years · Female only" }, "enrollment_count": 78, "start_date": "2013-08", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01900418" }, { "nct_id": "NCT00590785", "title": "Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Risk", "Breast Cancer", "Positive Nodes", "Cyclophosphamide", "Doxorubicin" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "tamoxifen", "type": "DRUG" }, { "name": "ciprofloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "1996-08-13", "completion_date": "2015-01-13", "has_results": false, "last_update_posted_date": "2017-08-25", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590785" }, { "nct_id": "NCT04899349", "title": "Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" }, { "name": "Dapagliflozin + metformin XR", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-04-06", "completion_date": "2023-05-10", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-15T10:29:58.297Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04899349" } ] }